```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:01 ON 18 SEP 2009)

     FILE 'REGISTRY' ENTERED AT 10:29:12 ON 18 SEP 2009
L1         37370 S BENZAZEPINE
L2         22737 S 937.72/RID
L3         10907 S 3-BENZAZEPINE
L4         16780 S 937.8/RID
L5       7316814 S 46.156/RID
L6          2382 S L4 AND L5
L7        240925 S CYCLOBUTYL
L8           279 S L6 AND L7
L9            91 S L8 AND NRS=3
L10           56 S L9 AND OXY
L11            0 S C21 H24 N3 O2
L12            0 S C21 H25 N3 O2
L13         3861 S C21 H25 N3 O2/MF
L14            5 S L10 AND L13
L15            4 S L14 AND N-METHYL
L16            3 S L15 AND 3-PYRIDINE
L17            1 S L16 NOT 11C

     FILE 'CAPLUS' ENTERED AT 10:43:14 ON 18 SEP 2009
L18            7 S L17

=> d ibib abs hitstr total
```

L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1073187 CAPLUS
DOCUMENT NUMBER: 149:315799
TITLE: Ppharmaceutical dosage form for oral administration
INVENTOR(S): Clarke, Allan James; Conn, Ian Paul; Hicks, Simon Richard; Li, Yu; Wang, Xiaolei
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 23pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008104589	A1	20080904	WO 2008-EP52429	20080228

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-892266P P 20070301

AB The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurol. and psychiatric disorders. Tablets containing 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methylnicotinamide were prepared

IT 720690-73-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical dosage form for oral administration)

RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:804087 CAPLUS
DOCUMENT NUMBER: 149:119663
TITLE: EEG-based determination of histamine 3 (H3) receptor bioactivity
INVENTOR(S): Radek, Richard J.; Bitner, R. Scott; Cowart, Marlon D.; Brioni, Jorge D.; Esbenshade, Timothy A.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080159958	A1	20080703	US 2007-950560		20071205
PRIORITY APPLN. INFO.:			US 2006-877275P	P	20061227

AB The invention discloses an in vivo method for determining the bioactivity of chemical compds. as histamine 3 receptor (H3R) ligands, and provides animal models to determine such bioactivity. The invention further discloses methods for screening therapeutic compds. demonstrating a desired property, using such methods and models described. Preparation of H3R antagonist (3aR, 6aR)-2-[4'-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1-yl)biphenyl-4-yl]-2H-pyridazin-3-one is described.

IT 720690-73-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GSK 189254A; EEG-based determination of histamine 3 (H3) receptor bioactivity)

RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:208237 CAPLUS
DOCUMENT NUMBER: 148:246365
TITLE: Polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1h-benzoo[d]azepin-7-yloxy)-n-methyl-nicotinamide hydrochloride for use in therapy
INVENTOR(S): Borrett, Gary Thomas; Wilson, David Matthew; Bailey, Nicholas; Steadman, Jon Graham
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: Brit. UK Pat. Appl., 20pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2441014	A	20080220	GB 2006-18135	20060914

PRIORITY APPLN. INFO.: GB 2006-18135 20060914

AB A polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride (I) is characterized by one or both of the following: an X-ray powder diffraction spectrum comprising peaks at 5% or greater relative intensity of 2 T box = 4.6 and 9.2 (corresponding to lattice spacings of 19.2 angstrom and 9.6 angstrom, resp.) an onset of melting in the range 233-240°C, as measured by DSC. The polymorph may be prepared by treating a solution of the free base, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide, in methanol with one equivalent of a chloride source (such as acetyl chloride or HCl), followed by crystallization with at least 1.5 vols. of Et acetate. The polymorph may be used in medicine to treat neurol., psychiatric, sleep and gastrointestinal disorders, pain, epilepsy and obesity. Preparation of I according to above method is disclosed, yield=77%.

IT 720690-73-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(polymorphic form of cyclobutylbenzodiazepin nicotinamide hydrochloride derivative for the treatment of neurol. diseases)

RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1050865 CAPLUS
DOCUMENT NUMBER: 143:347172
TITLE: Preparation of imidazoles as inhibitors of glutaminyl cyclase.
INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Heiser, Ulrich; Demuth, Hans-Ulrich
PATENT ASSIGNEE(S): Probiodrug Ag, Germany
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 838,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050215573	A1	20050929	US 2005-51760		20050204
US 7304086	B2	20071204			
US 20040224875	A1	20041111	US 2004-838993		20040505
US 7371871	B2	20080513			
ZA 2006005883	A	20071227	ZA 2006-5883		20050204
US 20090018087	A1	20090115	US 2007-923307		20071024
PRIORITY APPLN. INFO.:			US 2004-542133P	P	20040205
			US 2004-838993	A2	20040505
			US 2004-634364P	P	20041208
			US 2003-468014P	P	20030505
			US 2005-51760	A1	20050204

OTHER SOURCE(S): CASREACT 143:347172; MARPAT 143:347172
GI



I

AB Title compds. [I; A = (Ph-, cycloalkyl-interrupted) alkylene, alkenylene, alkynylene; B = NHC(:X)NHD, C(:X)NHD, C(:X)SD, etc.; D = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocyclyl, etc.; X = O, S, imino, (substituted) CH2], with specific exceptions, were prepared Thus, 3,4-methylenedioxyphenyl isothiocyanate and 3-(1H-imidazol-1-yl)propylamine were refluxed together for 2 h in EtOH to give 51.3% 1-[3-(1H-imidazol-1-yl)propyl]-3-(3,4-dimethoxyphenyl)thiourea. The latter showed an IC50 = 0.22 μM for inhibition of glutaminyl cyclase. Peptide inhibitors of dipeptidyl peptidase IV were also prepared
IT 720690-73-3, GSK 189254A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of imidazoles as inhibitors of glutaminyl cyclase)
RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	57	THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823672 CAPLUS
DOCUMENT NUMBER: 143:229851
TITLE: Preparation of imidazolyl thiourea derivatives as inhibitors of glutaminyl cyclase
INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Demuth, Hans-Ulrich; Heiser, Ulrich
PATENT ASSIGNEE(S): Probiodrug A.-G., Germany
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005075436	A2	20050818	WO 2005-EP1153		20050204
WO 2005075436	A3	20051208			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040224875	A1	20041111	US 2004-838993		20040505
US 7371871	B2	20080513			
AU 2005210004	A1	20050818	AU 2005-210004		20050204
CA 2554809	A1	20050818	CA 2005-2554809		20050204
EP 1713780	A2	20061025	EP 2005-707206		20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1918131	A	20070221	CN 2005-80004289		20050204
BR 2005007485	A	20070710	BR 2005-7485		20050204
JP 2007520520	T	20070726	JP 2006-551809		20050204
ZA 2006005883	A	20071227	ZA 2006-5883		20050204
IN 2006KN02139	A	20070518	IN 2006-KN2139		20060728
MX 2006008868	A	20061030	MX 2006-8868		20060804
KR 2006125884	A	20061206	KR 2006-717874		20060901
PRIORITY APPLN. INFO.:			US 2004-542133P	P	20040205
			US 2004-838993	A	20040505
			US 2004-634364P	P	20041208
			US 2003-468014P	P	20030505
			WO 2005-EP1153	W	20050204

OTHER SOURCE(S): CASREACT 143:229851; MARPAT 143:229851
GI



I



II

AB Title compds. I [A = alkyl, alkenyl, alkynyl, etc.; B = substituted thiourea, urea, amide, etc.] and their pharmaceutical acceptable salts, are prepared and disclosed as glutaminyl cyclase inhibitors. Thus, e.g., II was prepared by coupling of 1H-imidazole-1-propanamine with the corresponding isothiocyanate. The inhibitory activity of I towards DP IV was evaluated using chromogenic enzyme assay and it was revealed that selected compds. of the invention displayed Ki values in the range of 0.06 up to 204.5 μM. I as glutaminyl cyclase inhibitors should prove useful in the treatment of Alzheimer's disease, depression and dementia. Pharmaceutical compns. comprising I are disclosed.

IT 720690-73-3, GSK 189254A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drugs; preparation of imidazolyl thiourea derivs. as inhibitors of glutaminyl cyclase)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:547557 CAPLUS
DOCUMENT NUMBER: 143:53543
TITLE: The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist, and therapeutic use thereof
INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Hogg Willigers, Sandra
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005056056	A2	20050623	WO 2004-DK862		20041214
WO 2005056056	A3	20060202			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004296531	A1	20050623	AU 2004-296531		20041214
CA 2549574	A1	20050623	CA 2004-2549574		20041214
CA 2643922	A1	20050623	CA 2004-2643922		20041214
EP 1696896	A2	20060906	EP 2004-803015		20041214
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
BR 2004015899	A	20070109	BR 2004-15899		20041214
CN 1893935	A	20070110	CN 2004-80037386		20041214
JP 2007513896	T	20070531	JP 2006-543369		20041214
ZA 2006003397	A	20070926	ZA 2006-3397		20060428
MX 2006005127	A	20060711	MX 2006-5127		20060508
KR 2006124639	A	20061205	KR 2006-711860		20060615
NO 2006003267	A	20060713	NO 2006-3267		20060713
US 20070066601	A1	20070322	US 2006-596348		20060714
PRIORITY APPLN. INFO.:			DK 2003-1854	A	20031215
			US 2003-529491P	P	20031215
			WO 2004-DK862	W	20041214
			CA 2008-2549574	A3	20081212

AB The invention discloses the use of a serotonin reuptake inhibitor and a H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention

deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitor.

IT 720690-73-3, GSK 189254A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of serotonin reuptake inhibitor and H3 receptor antagonist, inverse agonist or partial agonist, and therapeutic use)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:546416 CAPLUS
DOCUMENT NUMBER: 141:106391
TITLE: Preparation of benzo[d]azepine derivatives as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurological disorders
INVENTOR(S): Bamford, Mark James; Dean, David Kenneth; Sehmi, Sanjeet Singh; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056369	A1	20040708	WO 2003-EP14556	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509413	A1	20040708	CA 2003-2509413	20031218
AU 2003294909	A1	20040714	AU 2003-294909	20031218
AU 2003294909	B2	20070517		
EP 1572215	A1	20050914	EP 2003-785885	20031218
EP 1572215	B1	20090902		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017483	A	20051116	BR 2003-17483	20031218
CN 1726042	A	20060125	CN 2003-80106364	20031218
CN 1326838	C	20070718		
JP 2006512412	T	20060413	JP 2005-502553	20031218
NZ 540148	A	20071130	NZ 2003-540148	20031218
ZA 2005004270	A	20060726	ZA 2005-4270	20050525
IN 2005DN02232	A	20070105	IN 2005-DN2232	20050526
US 20060040918	A1	20060223	US 2005-539385	20050616
US 7560452	B2	20090714		
MX 2005006567	A	20050816	MX 2005-6567	20050617
KR 765027	B1	20071009	KR 2005-711441	20050617
NO 2005003384	A	20050915	NO 2005-3384	20050712
US 20070299056	A1	20071227	US 2007-831191	20070731
KR 2007089762	A	20070831	KR 2007-719049	20070820
KR 897642	B1	20090514		
IN 2008DN07731	A	20081031	IN 2008-DN7731	20080912
US 20090105226	A1	20090423	US 2008-339145	20081219
PRIORITY APPLN. INFO.:			GB 2002-29820 A	20021220
			GB 2003-12607 A	20030602

WO 2003-EP14556	W	20031218
IN 2005-DN2232	A3	20050526
US 2005-539385	A3	20050616
KR 2005-711441	A3	20050617

OTHER SOURCE(S): MARPAT 141:106391
GI



I

AB The title compds. [I; R1 = cycloalkyl optionally substituted by alkyl; R2 = H, alkyl, X(cycloalkyl), X(aryl), etc.; X = a bond, alkyl; R3 = halo, alkyl, alkoxy, CN, NH2, CF3; n = 0-2], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 7-benzyloxy-1,2,4,5-tetrahydrobenzo[d]azepine (preparation given) with cyclobutanone in the presence of NaBH(OAc)3 afforded I [R1 = cyclobutyl; R2 = CH2Ph; n = 0] which showed pKb of 9.0-10.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.

IT 720690-73-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT:	18	THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT